TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06616584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study: NCT05929417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: END-IT intervention for the community setting
Description: The intervention was described in the arm/group descriptions.
Study: NCT05282121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avenciguat (BI 685509)
Description: Avenciguat (BI 685509)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study: NCT06059950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Flow Program
Description: The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
Study: NCT06616584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study: NCT06201520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual acupuncture
Description: manual acupuncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser acupuncture therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: sham laser acupuncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist splint
Description: wear wrist splint at night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist splint
Description: wear wrist splint at night

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: wrist splint
Description: wear wrist splint at night
Study: NCT06223529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Instrumental Music Performance
Description: Exercises using musical instruments to improve hemiparetic hand and arm function
Study: NCT06616584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT06616896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibration
Description: Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibration
Description: Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
Study: NCT06616064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalised feedback and brief motivational
Description: personalised feedback and brief motivational

Intervention type: OTHER
Group type: OTHER
Intervention: routine lifestyle advice
Description: routine lifestyle advice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine lifestyle advice
Description: routine lifestyle advice

Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire CliniCAP
Description: questionnaire CliniCAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire CliniCAP
Description: questionnaire CliniCAP
Study: NCT06616038

Intervention type: OTHER
Intervention: Data collection
Description: Given the observational nature of the study, the intervention is a simple data collection

Intervention type: OTHER
Intervention: Data collection
Description: Given the observational nature of the study, the intervention is a simple data collection
Study: NCT06677879

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week.
Study: NCT06678165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-204
Description: The intervention group will receive YOLT-204 on day0
Study: NCT06678204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized illustrated pamphlets
Description: Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
Study: NCT05540522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza modRNA vaccine
Description: Quadrivalent influenza modRNA vaccine (single dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza modRNA vaccine
Description: Quadrivalent influenza modRNA vaccine (single dose)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine
Description: Licensed quadrivalent influenza vaccine (single dose)
Study: NCT06217263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration device
Description: Vibracool vibration device from Pain Care Labs will be used.
Study: NCT05962931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioengineered Artificial Mesenchimal Sheet (BAMS)
Description: Each patient assigned to the experimental treatment group will receive 4 BAMS (1 BAMS/week) at a concentration of about 360,000 cells/cm2.
Study: NCT05128253

Intervention type: OTHER
Intervention: High fat meal in a subset of patients with NAFL or NASH
Description: In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
Study: NCT06217263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration device&Cold application pack
Description: Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
Study: NCT04992130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-season supplementary neurologic training program
Description: A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
Study: NCT05962931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (Control)
Description: Each patient assigned to the control group will undergo a standard treatment procedure for uncomplicated venous ulcers.
Study: NCT06520176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Day 1\~Day 2: 75mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Day 1\~Day 2: 200g/m\^2, q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Day 6: 6mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Day 1\~Day 2: 1～2g/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
Study: NCT06085352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TetraLens bandage contact lens
Description: Methafilcon-A contact lens eluding tetracaine ophthalmic solution

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Acuvue Oasys Bandage contact Lens
Description: Standard of care bandage contact lens
Study: NCT05540522

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine
Description: Licensed quadrivalent influenza vaccine (single dose)
Study: NCT05959772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation
Description: Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape
Study: NCT05943652

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: * Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
Study: NCT05195177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-histamine cream 1 hour
Description: At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic cream 1 hour
Description: At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
Study: NCT06364254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol Capsules
Description: 300 mg of cannabidiol administered 2 hours before 2 mile run

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol Capsules
Description: 300 mg of cannabidiol administered 2 hours before 2 mile run
Study: NCT04845516

Intervention type: OTHER
Intervention: Efficacy of apheresis
Description: Efficacy of apheresis

Intervention type: OTHER
Intervention: Efficacy of apheresis
Description: Efficacy of apheresis
Study: NCT06503549

Intervention type: OTHER
Intervention: Assessments
Description: Only the current assessments will be made

Intervention type: OTHER
Intervention: Assessments
Description: Only the current assessments will be made
Study: NCT05194995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab administered as an intravenous (IV) infusion.
Study: NCT06236646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai dance with twenty-five squares (TDT)
Description: The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control (CON)
Description: The CON group did not have any intervention but usual care.
Study: NCT05041504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation
Description: Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
Study: NCT05814133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber Laser
Description: Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
Study: NCT05041504

Intervention type: OTHER
Group type: OTHER
Intervention: Active wait list control
Description: Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
Study: NCT06337448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue LED
Description: The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
Study: NCT05232071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10 mg
Study: NCT05943652

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)

Intervention type: DIAGNOSTIC_TEST
Intervention: Tremor recording
Description: Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
Study: NCT05906225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG guided anesthesia
Description: Monitoring of electroencephalogram via Sedline probe by MASIMO corporation. Adjust concentration of inhalational sevoflurane during anesthesia, according to component of slow\&delta wave and alpha wave, so that slow/delta oscillation (with or without alpha oscillation) is maintained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional anesthesia
Description: Adjust concentration of inhalational sevoflurane during anesthesia, according to vital signs, so that mean blood pressure and heart rate are maintained between 80% and 120% of baseline values measured at ward before anesthesia.
Study: NCT05541393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention Group
Description: The intervention will involve meetings with the church health ministers to discuss COVID-19 vaccines and booster shots.
Study: NCT06556186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy
Description: Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptin 2.5mg, 2-3 times a day
Description: Bromocriptin 2.5mg, 2-3 times a day
Study: NCT04703855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3™ left ventricular assist system (HM3 LVAS)
Description: Advanced heart failure patients will be implanted with the HM3 LVAS
Study: NCT06125756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose KL001
Description: Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose KL001
Description: Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose KL001
Description: Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
Study: NCT04915911

Intervention type: OTHER
Intervention: cross-sectional study
Description: cross-sectional study
Study: NCT06494800

Intervention type: DIAGNOSTIC_TEST
Intervention: True cut needle biobsy
Description: The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
Study: NCT05183087

Intervention type: DIAGNOSTIC_TEST
Intervention: 3T Connectome MRI
Description: MRI scan of structural connectivity

Intervention type: DIAGNOSTIC_TEST
Intervention: 7 Tesla MRI
Description: MRI scan of functional connectivity

Intervention type: DIAGNOSTIC_TEST
Intervention: TSPO PET
Description: PET scan of neuroinflammation

Intervention type: DIAGNOSTIC_TEST
Intervention: Tau PET
Description: PET scan of tau deposition

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive and Behavioral Assessments
Description: Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers
Description: Blood-based assessments of proteomic and metabolic biomarkers of brain injury
Study: NCT04735731

Intervention type: DIAGNOSTIC_TEST
Intervention: Echography
Description: Echography of diaphragma and other respiratory muscles
Study: NCT05600881

Intervention type: DRUG
Intervention: Methylphenidate
Description: Participants will take their regular medication or a placebo (vitamin C)
Study: NCT04670406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT) combined with psychoeducation
Description: Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.